Khalid Garman, M.D., Ph.D., Cutaneous Development and Carcinogenesis Section, NIAMS

Contact Information

Media Resources

High Resolution Image

Summary

Khalid Garman, M.D., Ph.D, is a physician-scientist and visiting fellow in the Dermatology Branch at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and an adjunct faculty member at Georgetown University. With clinical knowledge and a strong background in pharmacology, he focuses on developing novel treatments for rare and aggressive skin cancers. Dr. Garman's research interest spans high-throughput screening and preclinical and clinical drug development, aiming to translate scientific discoveries into real-world therapies.

Beyond his research, Dr. Garman is dedicated to education and mentorship, teaching pharmacology at Georgetown University. He is also an active leader in the scientific community, contributing to organizations such as the American Society of Pharmacology and Experimental Therapeutics (ASPET). Dr. Garman strives to advance medical science and improve health outcomes through his commitment to innovation and collaboration.

Research Statement

Dr. Garman's research aims to develop innovative single-agent and combination therapies for Merkel cell carcinoma, a rare and aggressive skin cancer. His work utilizes advanced high-throughput screening techniques, including small-molecule, functional genomic, and synergy matrix screening, to identify promising drug targets and explore their underlying mechanisms of action.

Additionally, his research emphasizes drug repurposing by investigating FDA-approved or clinically tested drugs, aiming to accelerate treatment options for patients who do not respond to existing therapies.

Scientific Publications

High-throughput screening identifies Aurora kinase B as a critical therapeutic target for Merkel cell carcinoma.

Gelb T, Garman KA, Urban D, Coxon A, Gryder B, Hill NT, Miao L, Lee T, Lee O, Chakka S, Braisted J, Jarvis JE, Glavin R, Raj TS, Xiao Y, Difilippantonio S, Wang AQ, Shen M, Cheng KC, Lal-Nag M, Hall MD, Brownell I

Nat Commun.

2025 Feb 12;

16(1).

doi: 10.1038/s41467-025-56504-7

PMID: 39939315

Nuclear PKM2 binds pre-mRNA at folded G-quadruplexes and reveals their gene regulatory role.

Anastasakis DG, Apostolidi M, Garman KA, Polash AH, Umar MI, Meng Q, Scutenaire J, Jarvis JE, Wang X, Haase AD, Brownell I, Rinehart J, Hafner M

Mol Cell.

2024 Oct 3;

84(19).

doi: 10.1016/j.molcel.2024.07.025

PMID: 39153475

Mycophenolate mofetil inhibits Merkel cell carcinoma growth.

Garman KA, Thoreson N, Strong J, Hallaert P, Gelb T, Shen M, Hall MD, Brownell I

Br J Dermatol.

2024 Mar 15;

190(4).

doi: 10.1093/bjd/ljae018

PMID: 38266271

An Investigation of Structure-Activity Relationships and Cell Death Mechanisms of the Marine Alkaloids Discorhabdins in Merkel Cell Carcinoma Cells.

Orfanoudaki M, Smith EA, Hill NT, Garman KA, Brownell I, Copp BR, Grkovic T, Henrich CJ

Mar Drugs.

2023 Aug 29;

21(9).

doi: 10.3390/md21090474

PMID: 37755087

Identification of natural product modulators of Merkel cell carcinoma cell growth and survival.

Smith EA, Hill NT, Gelb T, Garman KA, Goncharova EI, Bokesch HR, Kim CK, Wendt KL, Cichewicz RH, Gustafson KR, Brownell I, Henrich CJ

Sci Rep.

2021 Jun 30;

11(1).

doi: 10.1038/s41598-021-93097-9

PMID: 34193920

Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism.

Tassi E, Garman KA, Schmidt MO, Ma X, Kabbara KW, Uren A, Tomita Y, Goetz R, Mohammadi M, Wilcox CS, Riegel AT, Carlstrom M, Wellstein A

Sci Rep.

2018 Oct 29;

8(1).

doi: 10.1038/s41598-018-34238-5

PMID: 30374109

Education

Georgetown University
Ph.D. in Pharmacology (2018)

Georgetown University
M.Sc. in Pharmacology (2012)

University of Tripoli
M.D. (2007)

Experience

Postdoctoral Fellowship
NIAMS (2018-Present)

Adjunct Faculty
Georgetown University (2016-Present)

Khalid Garman, M.D., Ph.D.

Postdoctoral Fellow (Visiting)

Cutaneous Development and Carcinogenesis Section